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Abstract 
Introduction: Sodium glucose cotransporter 2 (SGLT2) inhibitors are insulin-independent and glucose-dependent anti-hyperglycaemic 
drugs that have shown potential as an adjuvant therapy to insulin for the treatment of type 1 diabetes mellitus (T1DM). The purpose 
of this meta-analysis is to systematically collect available data from randomised trials to determine SGLT-2 inhibitor efficacy in terms of 
glycaemic control, body mass index, and renal protection when compared with placebo. 
Material and methods: Cochrane Library, MEDLINE, and EMBASE databases were searched for randomised controlled trials and meta-
analyses (without language restrictions) conducted from January 2010 to September 2019.
Results: Seventeen randomised controlled trials with 7325 participants were included. Sodium glucose cotransporter 2 therapy significantly 
reduced the level of glycated haemoglobin (HbA1c) (by 0.37%), body weight (by 2.88 kg), and estimated glomerular filtration (eGFR) (by 
0.67 mL/min/1.73 m²) when compared with placebo (all outcomes, p < 0.00001). Subgroup analysis by HbA1c levels showed significant 
differences between six and 12 months of treatment (p < 0.1). The magnitude of the HbA1c lowering effect waned with longer duration of 
treatment after six months (up to 12 months). Subgroup analysis by body weight showed significant differences between 1 and 3–4 months 
of treatment (p < 0.1). Weight loss plateaued after 3–4 months of treatment; subsequently, the weight remained relatively stable until 
12 months. Subgroup analysis by eGFR showed significant differences between six and 12 months of treatment (p < 0.1). The magnitude 
of the eGFR lowering effect increased with longer duration of treatment after six months (up to 12 months).
Conclusions: Sodium glucose cotransporter 2 inhibitors show significant therapeutic effects when compared with placebo. Although 
changes in HbA1c, body weight, and eGFR vary during treatment, the therapeutic effects of SGLT-2 inhibitors measured by these three 
outcomes can last up to 12 months. More long-term, randomised trials and extended studies are needed to determine the long-term ef-
fects of SGLT2 inhibitors as adjuvant therapy for T1DM patients.  (Endokrynol Pol 2020; 71 (4): 325–333)
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Introduction 
Type 1 diabetes mellitus (T1DM) is an autoimmune 
disease characterised by chronic hyperglycaemia due 
to an absolute deficiency of endogenous insulin and 
progressive metabolic alterations that increase the risk 
of cardiovascular diseases [1]. Type 1 diabetes affects 
about 22 million adults and 400,000 children, account-
ing for less than 5% of the total diabetes cases in the 
world [2]. Insulin replacement is still the main therapy 
for type 1 diabetes. Compared with conventional 
therapy, initial intensive therapy for diabetes has been 
shown to result in a moderate reduction in all-cause 
mortality [3]. However, intensive insulin therapy to 
achieve strict blood sugar control is usually associated 
with hypoglycaemia, and insulin cannot solve other 
important abnormalities associated with type 1 diabe-
tes, such as glucagon imbalance and increased gastric 
emptying rate (resulting in large and rapid fluctuations 
of postprandial blood glucose levels) [4]. In addition, 
insulin therapy itself is associated with weight gain and 
related hypertension [5]. Therefore, there is a need for 
adjuvant therapy that can improve key parameters 
continuously (such as glycated haemoglobin (HbA1c), 
weight, and length of time in which the correct blood 
glucose range is maintained) and which can reduce the 
hypoglycaemic risk. 
Sodium glucose cotransporter 2 (SGLT2) inhibitors 
are a new type of widely studied therapeutic adjuvants 
that can improve blood glucose control without relying 
on insulin. Sodium glucose cotransporter 2 inhibitors 
work by blocking glucose reabsorption in the renal 
proximal tubules, increasing urinary glucose excretion 
and heat and weight loss [6]. The safety and efficacy of 
SGLT-2 inhibitors for the treatment of type 2 diabetes 
have been confirmed in many studies [7–10]. On the 
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Other therapeutic, not double-blind, non-randomised studies, or 
those that involved non-human species, were excluded. Studies 
involving children and observational studies were also excluded.
Outcome measures
The main outcome measures of this analysis were: glycated hae-
moglobin (HbA1c) levels, body weight, and estimated glomerular 
filtration rate (EGFR) after 1, 3–4, 6, and 12 months of treatment, 
compared with placebo.
Data extraction and risk of bias assessment
Y.X. Huang and Z.J. Jiang performed data extraction and risk of 
bias assessment, respectively, and independently extracted the 
data in duplicate according to the Cochrane Intervention System 
Evaluation Manual, using a pre-designed data collection form. 
The extracted data included the following: the first author, year of 
publication, country, study population size, research and design, 
baseline characteristics of participants, and details of the experi-
mental and control interventions (including dose and follow-up 
times). Any disputes were settled by consensus. The quality of 
the randomised controlled trials was assessed by means of the 
Cochrane bias risk tool. The bias risk map and bias summary risk 
for this study are shown in the Supplementary Data Figure S1 
and S2. [16].
Data synthesis and analysis
The analysis was conducted using RevMan5.3 and Stata V.14.0 
software, following the Cochrane Manual for Systematic Evalua-
tion of Interventions [16], and was reported according to PRISMA 
Guidelines [17] (Preferred Reporting Item for Systematic Evalua-
tion and Meta-analysis). For continuous variables, we extracted the 
average difference between the intervention and control groups, 
and the corresponding standard deviation from baseline. When 
the standard deviation was not reported, it was obtained from the 
standard error, as described in the Cochrane manual. When only 
the difference between the average values of the two groups was 
reported, the standard deviation was also calculated according to 
the Cochrane Manual [16]. Heterogeneity was evaluated based 
on I² statistics. We used regression analysis to explore the reasons 
for results showing large heterogeneity [18]. Publication bias was 
visually assessed by drawing funnel plots and by performing Egger 
weighted regression tests [19]. We conservatively used the prior 
random effects model, assuming there were significant differences 
in therapeutic effects between studies.
Results
Literature retrieval and study selection
A database search led to the identification of 2711 eli-
gible research records, 298 of which were excluded due 
to duplication. After screening the titles and abstracts of 
the remaining 2413 studies, a total of 2386 studies were 
excluded based on the inclusion and exclusion criteria: 
24 were duplicates, 1756 involved type 2 diabetes, 134 
were animal experiments, 441 had no original data, and 
31 were unrelated. Finally, a total of 27 full articles were 
considered for further analysis. Because 10 of these were 
duplicates, a total of 17 studies evaluating the efficacy 
of SGLT2 combined with insulin therapy in patients 
with type 1 diabetes were included. The articles writ-
ten by Dandona 2017 and Dandona 2018 were about 
the same study but differed in the follow-up duration 
other hand, many studies of combined treatment of 
type 1 diabetes with SGLT-2 inhibitors and insulin have 
shown that SGLT-2 inhibitors effectively control blood 
sugar levels, reduce insulin demand, and promote 
weight loss. However, potential side effects, such as 
diabetic ketoacidosis and infection, have attracted wide-
spread scrutiny [11–14]. So far, the U.S. Food and Drug 
Administration (FDA) and the European Medicines 
Agency (EMA) have approved four SGLT2 inhibitors 
(canagliflozin, dapagliflozin, empagliflozin, and ertug-
liflozin). In addition, the double SGLT1/SGLT2 inhibi-
tor sotagliflozin has been approved by the EMA, and 
in Japan another three SGLT2 inhibitors (ipraglflozin, 
luseoglflozin, tofogliflozin) have been approved [28]. 
Previous meta-analyses [11–14] have confirmed 
the effectiveness of SGLT-2 inhibitors as adjuvant 
drugs. However, these reports did not analyse the ef-
fects of these drugs at different time points in detail. In 
addition, the duration of most registered trials is less 
than or equal to 24 weeks, but the therapeutic effects 
of drugs may differ when the observation period is 
prolonged. Therefore, we conducted a meta-analysis 
to determine the magnitude and persistence of the 
therapeutic effects of SGLT-2 inhibitors as auxiliary 
drugs when compared with placebo, focusing mainly 
on three outcomes: blood glucose control, body mass 
index, and renal protection.
Material and methods
Data sources and search
This study followed the preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015 guidelines 
[15]. We searched the MEDLINE, Embase, Cochrane Library (Janu-
ary 2010–October 30, 2019), and clinical trial.gov databases, as well 
as online reports of major diabetes conferences, for randomised 
controlled trials comparing the efficacy of SGLT-2 versus placebo in 
adult type 1 diabetic patients. We also checked the reference lists of 
the original studies and reviewed articles and meta-analyses down-
loaded electronically, to identify other qualifying reports. There were 
no language restrictions. The search terms were: “Dapagliflozin OR 
Empagliflozin OR Sotagliflozin OR Canagliflozin OR SGLT2 OR 
Sodium-Glucose Cotransporter 2 Inhibitor OR SGLT2 Inhibitor OR 
ipragliflozin OR Sodium Glucose Transporter 2 Inhibitors OR SGLT2 
Inhibitors” AND “Diabetes Mellitus, Type 1 [Mesh] OR Diabetes 
Mellitus, Type I OR Type 1 Diabetes OR Diabetes Mellitus, Ketosis-
Prone OR Diabetes, Autoimmune OR Diabetes Mellitus, Juvenile-
Onset OR Juvenile-Onset Diabetes OR Diabetes Mellitus, Insulin-
Dependent OR IDDM OR Diabetes Mellitus, Insulin-Dependent, 1 
OR Brittle Diabetes Mellitus OR Diabetes Mellitus, Sudden-Onset”.
Study selection
Eligible randomised trials had to meet the following criteria: 
 — they compared the efficacy and safety of SGLT2 inhibitors 
with placebo;
 — they were randomised controlled trials written in English or 
non-English languages
 — they compared SGLT2 inhibitors with placebo as adjunctive 
therapy to insulin for T1DM in patients aged 18 years or above, 
regardless of participant gender or race.
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(24 and 52 weeks, respectively). The entire process is 
summarised in Figure 1.
Research characteristics
All the studies included in this meta-analysis were 
double-blind, randomised controlled trials and were 
published as full-length articles from 2014 to 2018. The 
follow-up time in individual studies ranged from 1 
week to 52 weeks. Baseline characteristics were well 
balanced in the individual studies. A placebo was ad-
ministered in the control arm in all trials (Tab. 1).
Search results and quality assessment
Glycated haemoglobin (HbA1c)
The meta-analysis revealed that SGLT2 therapy signifi-
cantly reduced HbA1c levels by 0.37% (weighted mean 
difference [WMD]: –0.37%; 95% confidence interval 
[CI]: –0.41, –0.33; I2 = 99%; p < 0.00001). The subgroup 
analysis indicated that all subgroups showed statistical 
significance, including the 1-month subgroup (WMD: 
–0.43%; 95% CI: –0.59, –0.27; I2 = 0%; p < 0.00001), 
the 3–4-months subgroup (WMD: –0.38%; 95% CI: 
–0.51, –0.25; I2 = 91%; p < 0.00001), the 6-months sub-
group (WMD: –0.40%; 95% CI: –0.44, –0.36; I2 = 99%; 
p < 0.00001), and the 12-months subgroup (WMD: 
–0.30%; 95% CI: –0.35, –0.26; I2 = 98%; p < 0.00001). 
Moreover, the 1-month subgroup showed no significant 
difference with the 3–4-months subgroup. Similarly, the 
3–4-months subgroup showed no significant difference 
with the 6-months subgroup. However, there was a sig-
nificant difference between the 6-months subgroup and 
the 12-months subgroup (p < 0.1). The magnitude of 
the HbA1c lowering effect waned with longer duration 
of treatment after six months (up to 12 months) (Fig. 2).
Body weight
The meta-analysis revealed that SGLT2 therapy sig-
nificantly reduced body weight by 2.88 kg (WMD: 
–2.88; 95% CI: –3.11, –2.65; I2 = 99%; p < 0.00001). 
The subgroup analysis indicated that all subgroups 
showed statistically significant differences with placebo, 
including the 1-month subgroup (WMD: –1.77; 95% 














































Figure 1. Flowchart of the literature screening
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subgroup (WMD: –2.83; 95% CI: –3.90, –1.76; I2 = 86%; 
p < 0.00001), the 6-months subgroup (WMD: –2.87; 
95% CI: –3.19, –2.55; I2 = 100%; p < 0.00001), and the 
12-months subgroup (WMD: –3.21; 95% CI: –3.86, 
–2.55; I2 = 100%; p < 0.00001). Moreover, the 1-month 
subgroup showed a significant difference with the 
3–4-months subgroup (p < 0.1), but the 3–4-months 
subgroup showed no significant difference with the 
6-months subgroup. Similarly, there was no signifi-
cant difference between the 6-months subgroup and 
the 12-months subgroup. Weight loss plateaued after 
3–4 months of treatment, but thereafter the weight 
remained relatively stable and was maintained until 
12 months (Fig. 3).
Estimated glomerular filtration rate (eGFR)
The meta-analysis revealed that SGLT2 therapy signifi-
cantly reduced the eGFR by 0.67 mL/min/1.73 m² (WMD: 
–0.67; 95% CI: –0.71, –0.63; I2 = 100%; p < 0.00001). The 
subgroup analysis indicated that both the 6-months 
subgroup (WMD: –0.51; 95% CI: –0.55, –0.46; I2 = 100%; 
p < 0.00001) and the 12-months subgroup showed 
statistically significant differences with placebo (WMD: 
–1.32; 95% CI: –1.42, –1.23; I2 = 72%; p < 0.00001). 
Moreover, there was a significant difference between 
the 6-months subgroup and the 12-months subgroup 
(p < 0.1). Hence, the eGFR lowering effect increased 
with longer duration of treatment after six months (up 
to 12 months) (Fig. 4).
Evaluated parameters in different time-points
Figure 5 shows the reduction of HbA1c (black line) com-
pared with the control group in different follow-up 
time (1 month, 3–4 months, 6 months, 12 months); 
it also shows the reduction of body weight (red 
line) compared with the control group in different 
follow-up time (1 month, 3–4 months, 6 months, 
12 months), and that the reduction of eGFR (blue 
line) compared with the control group in different 
follow-up time (6 months, 12 months). The data are 
represented by the table included in the figure. The 
analysis was performed with log-transformed values 
Figure 2. Forest plot of mean difference in glycated haemoglobin (HbA1c). Horizontal lines represent the 95% confidence interval (CI). 
Solid squares indicate the mean difference and are proportional to the weights used in the meta-analysis. Solid vertical line indicates no 
effect. Diamond indicates the weighted mean difference (WMD); the lateral tips of the diamond indicate the associated 95% CI 
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by analysis of covariance and corrected for the baseline 
values. In both panels, means and 95% confidence 
intervals are shown.
Risk of bias in the study and meta-regression
We used the Cochrane Risk Bias Assessment Tool includ-
ed in Revman 5.3 to assess bias in the 17 randomised 
Figure 3. Forest plot of mean difference in body weight. Horizontal lines represent the 95% confidence interval (CI). Solid squares 
indicate the mean difference and are proportional to the weights used in the meta-analysis. Solid vertical line indicates no effect. Diamond 
indicates the weighted mean difference (WMD); the lateral tips of the diamond indicate the associated 95% CI
Figure 4. Forest plot of mean difference in estimated glomerular filtration rate (eGFR). Horizontal lines represent the 95% confidence 
interval (CI). Solid squares indicate the mean difference and are proportional to the weights used in the meta-analysis. Solid vertical line 
indicates no effect. Diamond indicates the weighted mean difference (WMD); the lateral tips of the diamond indicate the associated 95% CI
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trials and constructed a bias risk map and a bias risk 
summary map. We identified three studies with one 
high risk of bias, six studies with one or two unknown 
risks of bias, and eight high-quality studies. We con-
ducted meta-regression on the outcome indicators 
showing large heterogeneity to explore the causes of 
the heterogeneity, and finally only the HbA1c results 
showed statistical significance. Our meta-regression 
analysis detected a linear correlation between HbA1c 
levels and follow-up time (regression coefficient 1.003; 
p = 0.013) (Supplementary File — Figure S3).
Discussion
Short and medium-term efficacy of sodium glucose 
cotransporter 2 inhibitors are a new class of antidiabetic 
drugs, which work independently of insulin. They 
have been shown to improve blood sugar control, 
body weight, and blood pressure in T2DM [9]. Previous 
studies [12, 13] also confirmed that SGLT2 inhibitors are 
effective when used to treat T1DM. Because adjuvant 
drug therapy for type 1 diabetes is usually long-term, it 
is crucial to determine the magnitude and persistence 
of the therapeutic effects of these agents. In this review, 
we summarise the data of 17 clinical trials conducted 
in patients with type 1 diabetes. When the results of all 
the placebo-controlled trials were combined, we found 
that although changes in HbA1c, body weight, and eGFR 
differed during the treatment period, the therapeutic 
effects of the SGLT-2 inhibitors, based on these three 
outcomes, could last up to 12 months. At present, there 
are no large-scale experiments longer than 12 months 
to determine the duration of the therapeutic effects of 
SGLT2 inhibitors in patients with type 1 diabetes. 
Glycosylated haemoglobin (A1c) is an effective sur-
rogate marker for evaluating the success of long-term 
diabetes treatment. According to the U.S. Food and 
Drug Administration (FDA), the primary endpoint to 
determine the efficacy of drugs that lower blood glucose 
levels should be A1c reduction [37]. HbA1c has been 
proven to be highly valuable for patient management, 
it is an important measure of population health, and is 
still an effective indicator of glycation as a complicating 
risk factor [38]. Controlling glycosylated haemoglobin 
levels reduces the side effects of insulin therapy in 
T1DM patients. Based on our meta-analysis, SGLT2 
inhibitors show a relatively stable HbA1c lowering ef-
fect during the first six months of treatment, but then it 
wanes after six months of treatment (up to 12 months).
Compared with short-term treatment, long-term 
treatment with SGLT2 inhibitors can lead to continuous 
weight loss. These findings are important. Although 
significant progress has been made in insulin prepara-
tion, delivery systems, and blood glucose monitoring, 
only one third of patients achieve the desired blood 
glucose target, and many patients become overweight 











or obese [39–41]. Previous evidence shows that moder-
ate weight loss is associated with a beneficial reduction 
of cardiovascular risk factors [42, 43]. Losing weight 
may also help patients get psychological support from 
treatment plans. Based on our meta-analysis, weight 
loss plateaued after 3-4 months of treatment with SGLT2 
inhibitors; thereafter, the weight was relatively stable 
up to 12 months. 
In the early stages of diabetes, the glomerular filtra-
tion rate can increase, and this is one of the mechanisms 
of diabetic nephropathy. The early effects of SGLT2 
inhibitors on glomerular ultrafiltration and urinary 
protein excretion are an indication of their potential 
renal protective effects [11]. Our study showed that 
the eGFR lowering effect increased after six months of 
treatment (up to 12 months). Hence, SGLT2 inhibitors 
as adjuvant drugs in T1DM also have long-term renal 
protective effects.
EI Masri et al. [13] carried out two subgroup analy-
ses of dose and treatment duration, but only included 
four randomised controlled trials and only analysed 
the effects of dose and treatment duration on HbA1c 
and body weight, two outcome indicators. Xu et al. 
[12] performed a meta-analysis, together with three 
gradient dose sub-analyses, of SGLT2 inhibitors in 
T1DM, and pointed out that more sub-analyses were 
needed, such as long- and short-term treatment 
analyses. In addition to previous studies [12], four new 
studies [24, 30, 31, 34] have been added to the current 
meta-analysis, including the experimental results of 
the new drug ipragliflozin [30, 31]. Hence, this is the 
most comprehensive and reliable meta-analysis so far, 
including 17 trials. We performed subgroup analysis 
based on treatment duration at four time points and 
analysed changes in HbA1c, body weight, and eGFR 
over time. The extensive data collected in this study 
allows us to compare SGLT2 inhibitors and placebo at 
different time points, revealing the effects of SGLT-2 
inhibitors over time. We also explored heterogeneity 
and identified the heterogeneous sources of glycosyl-
ated haemoglobin. Unfortunately, we were unable to 
successfully explore the heterogeneous source of other 
parameters. We studied the overall effects of SGLT2 
inhibitors as a class of drugs, and in the process, we 
may have neglected to consider the influence of dif-
ferent drug types. The therapeutic effects may also be 
influenced by the characteristics of the participants in 
clinical trials and may differ for different molecules. In 
addition, most of this research is industry-funded, 
which may lead to further bias. We may also have 
missed unpublished reports. Many other reasons can 
explain the observed heterogeneity, and these view-
points deserve further attention in specially designed 
meta-analyses.
Conclusion
This review provides information about the thera-
peutic effects of SGLT2 inhibitors in T1DM. More 
long-term randomised trials are needed to determine 
the long-term effects of SGLT2 inhibitors as adjuvants 
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